Citations 2
Cognitive dispersion profiles and prediction of cognitive change in early‐onset dementias: Results from LEADS
Hammers, Dustin B., Foster, Elodie, Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra, Joie, Renaud La, Beckett, Laurel, Gao, Sujuan, Vemuri, Prashanthi, Nudelman, Kelly N., Kirby, Kala, Dage, Jeffrey L., Aisen, Paul, Atri, Alireza, Clark, David G., Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalski, Emily, Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Dickerson, Bradford C., Rabinovici, Gil D., Carrillo, Maria C., Apostolova, Liana G., Joie, Renaud La , La Joie, Renaud , Hammers, Dustin B , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Touroutoglou, Alexandra , Beckett, Laurel , Gao, Sujuan , Vemuri, Prashanthi , Nudelman, Kelly , Kirby, Kala, Dage, Jeffrey L. , Aisen, Paul , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Rabinovici, Gil D. , Carrillo, María C. , Apostolova, Liana G.
Alzheimer's & Dementia | May 19, 2026 | Volume: 22 | Issue: 5 | Pages: No page available
Abstract INTRODUCTION Research into cognitive dispersion – a cognitive process score measuring the intra‐individual variability (IIV) across a single testing session – suggests utility in neurodegenerative populations. Given widespread deficits observed in sporadic early‐onset Alzheimer's disease (EOAD), however, it is unclear if examining cognitive dispersion shows benefit in this condition. METHODS A total of 309 participants (188 amyloid‐positive EOAD, 43 amyloid‐negative early‐onset dementia [EOnonAD], 78 cognitively normal [CN]) completed neuropsychological testing twice over 12 months. Dispersion‐related differences among groups were assessed, as was cognitive dispersion's capacity to predict domain‐specific cognitive trajectories, and its convergence with imaging biomarkers. RESULTS EOAD participants displayed higher cognitive dispersion than EOnonAD participants, and associations with EOAD‐specific biomarkers. Additionally, cognitive dispersion was associated with 12‐month reliable change across several cognitive domains. DISCUSSION These preliminary results examine cognitive dispersion in sporadic EOAD. When used with baseline cognitive performance, cognitive dispersion measures may enrich future clinical trials in EOAD by enhancing treatment monitoring over time.
Criterion and convergent validity of plasma biomarkers in early‐onset Alzheimer's disease: Initial findings from LEADS
Hammers, Dustin B., Polsinelli, Angelina, Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana, Gao, Sujuan, Beckett, Laurel, Joie, Renaud La, Touroutoglou, Alexandra, Vemuri, Prashanthi, Zetterberg, Henrik, Blennow, Kaj, Nemes, Sára , Костадинова, Ралица, Aisen, Paul, Nudelman, Kelly N., Kirby, Kala, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Dage, Jeffrey L., Apostolova, Liana G., Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Polsinelli, Angelina J. , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana , Gao, Sujuan , Beckett, Laurel , Touroutoglou, Alexandra , Vemuri, Prashanthi , Zetterberg, Henrik , Blennow, Kaj , Kostadinova, Ralitsa, Aisen, Paul , Nudelman, Kelly , Kirby, Kala, Atri, Alireza , Clark, David, Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Dage, Jeffrey L. , Apostolova, Liana G.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 4, 2026 | Volume: 18 | Issue: 2 | Pages: No page available
Abstract INTRODUCTION : Despite expanding use of plasma biomarkers for Alzheimer's disease (AD), minimal examination has been undertaken in early‐onset AD (EOAD). Prior analyses assessed criterion and convergent validity of common plasma biomarkers in a well‐characterized sample with sporadic EOAD. METHODS : Plasma amyloid beta (Aβ) 42/40, tau phosphorylated at threonine 231 (p‐tau231), glial fibrillary acidic protein (GFAP), and neurofilament light change (NfL) levels were obtained for 189 EOAD, 52 early‐onset non‐AD (EOnonAD), and 83 cognitively normal (CN) participants. Diagnostic group differences, convergence with imaging biomarkers, and the capacity to predict specific cognitive domains were investigated. RESULTS : After controlling for cognitive status, EOAD participants exhibited more pathologic levels of Aβ42/40, p‐tau231, and GFAP relative to EOnonAD participants. However, NfL displayed the greatest sensitivity to non‐amnestic cognitive impairment across the sample. DISCUSSION : These results establish criterion and convergent validity of plasma biomarkers in sporadic EOAD and highlight complementary roles that AD‐specific and non‐specific plasma markers may play across the course of AD care.